GLSI - Greenwich LifeSciences, Inc.

9.07
-0.520   -5.733%

Share volume: 446,027
Last Updated: 04-08-2025
Pharmaceutical Products/Pharmaceutical Preparations: 0.05%

PREVIOUS CLOSE
CHG
CHG%
$9.59
-0.52
-0.05%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
28%
Profitability 0%
Dept financing 29%
Liquidity 50%
Performance 50%
Company vs Stock growth
vs
N/A
12.990 13.590
0.600 4.62%
+ Add row to compare
Performance
5 Days
2.72%
1 Month
-21.88%
3 Months
-26.74%
6 Months
-29.96%
1 Year
-45.46%
2 Year
-28.30%
Key data
Stock price
$9.07
P/E Ratio 
0.00
DAY RANGE
$8.72 - $10.00
EPS 
-$0.59
52 WEEK RANGE
$8.06 - $18.75
52 WEEK CHANGE
-$42.70
MARKET CAP 
188.889 M
YIELD 
N/A
SHARES OUTSTANDING 
13.145 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
04-14-2025
BETA 
1.80
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$271,372
AVERAGE 30 VOLUME 
$112,238
Company detail
CEO: Snehal S. Patel
Region: US
Website: greenwichlifesciences.com
Employees: 3
IPO year: 2020
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Greenwich LifeSciences focuses on the development of novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is the GP2, an immunotherapy, which has completed Phase IIb clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery.

Recent news
loading